In Brief: Novo Nordisk
Executive Summary
Novo Nordisk: Sanofi will market Novo Nordisk's anti-epileptic Gabitril outside of the Americas and Japan. Sanofi already markets the epilepsy treatment Depakine. Abbott has rights to Gabitril in North America and Mexico. Gabitril was approved by FDA on Sept. 30...